{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:33:48Z","timestamp":1790051628367,"version":"4.0.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA) are at high risk of deep vein thrombosis (DVT) postoperatively, necessitating the use of prophylaxis medications. This investigation used a large claims database to evaluate trends in postoperative DVT prophylaxis and rates of DVT within 6 months after THA or TKA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Truven Health MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases were reviewed from 2004 to 2013 for patients who underwent THA or TKA. Data were collected on patient age, sex, Charlson Comorbidity Index, and hypercoagulability diagnoses. Postoperative medication claims were reviewed for prescribed aspirin, warfarin, enoxaparin, fondaparinux, rivaroxaban, and dabigatran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 369,483 patients were included in the analysis, of which 239,949 patients had prescription medication claims. Warfarin was the most commonly prescribed anticoagulant. Patients with a hypercoagulable diagnosis had markedly more DVTs within 6 months after THA or TKA. More patients with a hypercoagulable diagnosis were treated with warfarin or lovenox than other types of anticoagulants. A multivariate regression analysis was performed, showing that patients prescribed aspirin, fondaparinux, and rivaroxaban were markedly less likely than those prescribed warfarin or enoxaparin to have a DVT within 6 months after THA or TKA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>After THA and TKA, warfarin is the most commonly prescribed prophylaxis. Patients with hypercoagulability diagnoses are at a higher risk of postoperative DVT. The likelihood of DVT within 6 months of THA and TKA was markedly higher in patients treated with warfarin and lovenox and markedly lower in those treated with aspirin, fondaparinux, and rivaroxaban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>Level III<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5435\/jaaos-d-17-00235","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T12:44:13Z","timestamp":1535546653000},"page":"698-705","source":"Crossref","is-referenced-by-count":57,"title":["Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty"],"prefix":"10.5435","volume":"26","author":[{"given":"Harpreet","family":"Bawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Weick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Dirschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hue H.","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230714","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2106\/JBJS.N.01141","article-title":"Prevalence of total hip and knee replacement in the United States","volume":"97","author":"Maradit Kremers","year":"2015","journal-title":"J Bone Joint Surg Am"},{"key":"R2-20230714","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0883-5403(97)90195-9","article-title":"Causes of death after hip arthroplasty in primary arthrosis","volume":"12","author":"Visuri","year":"1997","journal-title":"J Arthroplasty"},{"key":"R3-20230714","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199009203231206","article-title":"Total hip and total knee replacement","volume":"323","author":"Harris","year":"1990","journal-title":"N Engl J Med"},{"key":"R4-20230714","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2106\/00004623-200203000-00021","article-title":"Prophylaxis against venous thromboembolic disease in patients having a total hip or knee arthroplasty","volume":"84","author":"Sculco","year":"2002","journal-title":"J Bone Joint Surg"},{"key":"R5-20230714","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"R6-20230714","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.08-2655","article-title":"American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: What are the implications for clinicians and patients?","volume":"135","author":"Eikelboom","year":"2009","journal-title":"Chest"},{"key":"R7-20230714","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1302\/0301-620X.94B11.30824","article-title":"Current guidelines for total joint VTE prophylaxis: Dawn of a new day","volume":"94","author":"Barrack","year":"2012","journal-title":"J Bone Joint Surg Br"},{"key":"R8-20230714","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.arth.2012.06.001","article-title":"Complications related to therapeutic anticoagulation in total hip arthroplasty","volume":"28","author":"McDougall","year":"2013","journal-title":"J Arthroplasty"},{"key":"R9-20230714","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.arth.2007.03.007","article-title":"Does \u201cexcessive\u201d anticoagulation predispose to periprosthetic infection?","volume":"22","author":"Parvizi","year":"2007","journal-title":"J Arthroplasty"},{"key":"R10-20230714","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1007\/s11999-008-0209-4","article-title":"Periprosthetic joint infection: The incidence, timing, and predisposing factors","volume":"466","author":"Pulido","year":"2008","journal-title":"Clin Orthop Relat Res"},{"key":"R11-20230714","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.2106\/JBJS.I.00511","article-title":"American Academy of Orthopaedic Surgeons Clinical Practice guideline on: Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty","volume":"91","author":"Johanson","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"R12-20230714","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1001\/jama.1992.03480210073035","article-title":"Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement","volume":"267","author":"Francis","year":"1992","journal-title":"JAMA"},{"key":"R13-20230714","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.arth.2014.08.032","article-title":"The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: How often are patients within their target INR range?","volume":"30","author":"Nam","year":"2015","journal-title":"J Arthroplast"},{"key":"R14-20230714","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.arth.2012.12.007","article-title":"Warfarin for thromboprophylaxis following total joint arthroplasty: Are patients safely anti-coagulated?","volume":"28","author":"Aynardi","year":"2013","journal-title":"J Arthroplasty"},{"key":"R15-20230714","first-page":"1295","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary embolism prevention (PEP) trial","volume":"355","year":"2015","journal-title":"Lancet"},{"key":"R16-20230714","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/01.blo.0000238826.63648.c5","article-title":"Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty","volume":"452","author":"Colwell","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"R17-20230714","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1345\/aph.1R331","article-title":"Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: A comparison of the AAOS and ACCP guidelines with review of the evidence","volume":"47","author":"Stewart","year":"2013","journal-title":"Ann Pharmacother"},{"key":"R18-20230714","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.3928\/0147-7447-20030202-06","article-title":"Managing thromboembolic risk in hip and knee arthroplasty: State of the art","volume":"26","author":"Colwell","year":"2003","journal-title":"Orthopedics"},{"key":"R19-20230714","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"R20-20230714","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1302\/0301-620X.77B1.7822397","article-title":"Death and thromboembolic disease after total hip replacement: A series of 1162 cases with no routine chemical prophylaxis","volume":"77","author":"Warwick","year":"1995","journal-title":"J Bone Joint Surg Br"},{"key":"R21-20230714","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.arth.2006.03.006","article-title":"The effectiveness of warfarin dosing from a nomogram compared with house staff dosing","volume":"22","author":"Asnis","year":"2007","journal-title":"J Arthroplasty"},{"key":"R22-20230714","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1524-4733.2003.00204.x","article-title":"Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States","volume":"6","author":"Caprini","year":"2003","journal-title":"Value Health"},{"key":"R23-20230714","first-page":"376","article-title":"Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: A systematic review and meta-analysis","volume":"51","author":"Sobieraj","year":"2012","journal-title":"Bone"},{"key":"R24-20230714","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00264-013-2134-8","article-title":"Antithrombotic prophylaxis in major orthopaedic surgery: An historical overview and update of current recommendations","volume":"38","author":"Kinov","year":"2014","journal-title":"Int Orthop"},{"key":"R25-20230714","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/th15-07-0527","article-title":"Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty","volume":"115","author":"Kim","year":"2016","journal-title":"Thromb Haemost"},{"key":"R26-20230714","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jhm.2224","article-title":"Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: A systematic review and meta-analysis","volume":"9","author":"Drescher","year":"2014","journal-title":"J Hosp Med"},{"key":"R27-20230714","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.arth.2015.06.045","article-title":"Thromboembolism prophylaxis in hip arthroplasty: Routine and high risk patients","volume":"30","author":"Nam","year":"2015","journal-title":"J Arthroplasty"},{"key":"R28-20230714","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1160\/TH11-07-0463","article-title":"Evaluation of the duration of thromboembolic prophylaxis after high-risk orthopaedic surgery: The ETHOS observational study","volume":"107","author":"Bergqvist","year":"2012","journal-title":"Thromb Haemost"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00124635-201810010-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:49:21Z","timestamp":1787669361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00124635-201810010-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":28,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-17-00235","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}